Development of a Biomarker Signature Associated with Anoikis to Predict Prognosis and Immunotherapy Response in Melanoma

Overview

Journal Arch Dermatol Res

Specialty Dermatology

Date 2024 May 24

PMID 38787413

Authors

Zhixuan Wu

Rongrong Zhang

Jingxia Bao

Mengqi Yin

Xiaowu Wang

Affiliations

Soon will be listed here.

Abstract

Skin cutaneous melanoma (SKCM) is malignant cancer known for its high aggressiveness and unfavorable prognosis, particularly in advanced tumors. Anoikis is a specific pattern of programmed cell death associated with tumor regeneration, migration, and metastasis. Nevertheless, limited research has been conducted to investigate the function of anoikis in SKCM. Anoikis-related genes (ARGs) were extracted from Genecards to identify SKCM subtypes and to explore the immune microenvironment between the different subtypes. Prognostic models of SKCM were developed by LASSO COX regression analysis. Subsequently, the predictive value of risk scores in SKCM and the association with immunotherapy were further explored. Finally, the expression of 6 ARGs involved in the model construction was detected by immunohistochemistry and PCR. This study identified 20 ARGs significantly associated with SKCM prognosis and performed disease subtype analysis of samples based on these genes, different subtypes exhibited significantly different clinical features and tumor immune microenvironment (TIME) landscapes. The risk score prognostic model was generated by further screening and identification of the six ARGs. The model exhibited a high degree of sensitivity and specificity to predict the prognosis of individuals with SKCM. These high- and low-risk populations showed different immune statuses and drug sensitivity. Further immunohistochemical and PCR experiments identified significant differential expression of the six ARGs in tumor and normal samples. Anoikis-based features may serve as novel prognostic biomarkers for SKCM and may provide important new insights for survival prediction and individualized treatment development.

References

Gandini S, Autier P, Boniol M . Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol. 2011; 107(3):362-6. DOI: 10.1016/j.pbiomolbio.2011.09.011. View

Ahmed B, Qadir M, Ghafoor S . Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment. Crit Rev Eukaryot Gene Expr. 2020; 30(4):291-297. DOI: 10.1615/CritRevEukaryotGeneExpr.2020028454. View

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N . European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer. 2022; 170:236-255. DOI: 10.1016/j.ejca.2022.03.008. View

Frauchiger A, Mangana J, Rechsteiner M, Moch H, Seifert B, Braun R . Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. Br J Dermatol. 2015; 174(4):823-30. DOI: 10.1111/bjd.14347. View

Raigani S, Cohen S, Boland G . The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. Curr Oncol Rep. 2017; 19(3):17. DOI: 10.1007/s11912-017-0575-8. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

Carlino M, Larkin J, Long G . Immune checkpoint inhibitors in melanoma. Lancet. 2021; 398(10304):1002-1014. DOI: 10.1016/S0140-6736(21)01206-X. View

Guo W, Wang H, Li C . Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther. 2021; 6(1):424. PMC: 8685279. DOI: 10.1038/s41392-021-00827-6. View

Wernicke A, Polce S, Parashar B . Role of Radiation in the Era of Effective Systemic Therapy for Melanoma. Surg Clin North Am. 2019; 100(1):189-199. DOI: 10.1016/j.suc.2019.09.010. View

10.

Luke J, Flaherty K, Ribas A, Long G . Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017; 14(8):463-482. DOI: 10.1038/nrclinonc.2017.43. View

11.

Han H, Sung J, Kim S, Yun U, Kim H, Jang E . Fibronectin regulates anoikis resistance via cell aggregate formation. Cancer Lett. 2021; 508:59-72. DOI: 10.1016/j.canlet.2021.03.011. View

12.

Dias Amoedo N, Rodrigues M, Rumjanek F . Mitochondria: are mitochondria accessory to metastasis?. Int J Biochem Cell Biol. 2014; 51:53-7. DOI: 10.1016/j.biocel.2014.03.009. View

13.

Zhong X, Rescorla F . Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal. 2011; 24(2):393-401. DOI: 10.1016/j.cellsig.2011.10.005. View

14.

Adeshakin F, Adeshakin A, Afolabi L, Yan D, Zhang G, Wan X . Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming. Front Oncol. 2021; 11:626577. PMC: 8039382. DOI: 10.3389/fonc.2021.626577. View

15.

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

16.

Shi T, Zhang C, Xia S . The potential roles and mechanisms of non-coding RNAs in cancer anoikis resistance. Mol Cell Biochem. 2022; 477(5):1371-1380. DOI: 10.1007/s11010-022-04384-6. View

17.

Khan S, Fatima K, Malik F . Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis. Clin Exp Metastasis. 2022; 39(5):715-726. DOI: 10.1007/s10585-022-10172-9. View

18.

Chen Y, Guo L, Zhou Z, An R, Wang J . Identification and validation of a prognostic model for melanoma patients with 9 ferroptosis-related gene signature. BMC Genomics. 2022; 23(1):245. PMC: 8969311. DOI: 10.1186/s12864-022-08475-y. View

19.

Yang Y, Li Y, Qi R, Zhang L . Development and Validation of a Combined Glycolysis and Immune Prognostic Model for Melanoma. Front Immunol. 2021; 12:711145. PMC: 8517401. DOI: 10.3389/fimmu.2021.711145. View

20.

Riefolo M, Porcellini E, Dika E, Broseghini E, Ferracin M . Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. Mol Oncol. 2018; 13(1):74-98. PMC: 6322194. DOI: 10.1002/1878-0261.12412. View